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              Susanne Gollin, PhD 
The American Cancer Society estimates that >500,000 new cases of squamous cell 
carcinomas of the head and neck (SCCHN) are diagnosed each year.  Although the incidence 
varies widely around the world, it is especially high in developing countries and is positively 
associated with higher rates of exogenous risk factors including, smoking, alcohol use, and viral 
infection. But, only a fraction of the people in these high-risk groups will develop the disease.  
Treatment times tend to be long and costly with survival rates averaging 50%, one of the lowest 
for the major cancers. Therefore, further work is needed to aid in our understanding of genetic 
and environmental risk factors, as well as the underlying biology of SCCHN.  To further assess 
the etiology of SCCHN, the study used the approach of examining one candidate gene, the 
Ataxia Telangiectasia Mutated gene (ATM), located at 11q22.3 and functioning in the DNA 
damage response/repair pathway.  Compared to other cancers, SCCHN tumors exhibit a very 
high rate of chromosomal instability, often showing amplification of chromosome 11q13 and 
loss of 11q22-qter.  We hypothesized that SCCHN patients (cases) have a higher incidence of 
germline alterations in ATM than controls.  Three hundred cases and 360 controls were 
genotyped for nine ATM tag-SNPs and supplemented with one splice-site SNP.   Logistic 
regression analysis showed that two SNPs (rs611646 and rs373759) were associated with 
increased risk of developing SCCHN: P = 0.012 and P = 0.025, respectively.  In SNP rs611646, 
the TT genotype was more common in cases than controls (45 versus 32%) while the AA and 
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AT genotypes were less common in cases than controls (18 versus 21% and 37 versus 46%, 
respectively).  In SNP rs373759, the CC genotype was more common in cases than controls (56 
versus 48%) with the CT type being less common in cases than controls (29 versus 40%).  
Genetic studies such as this could have a public health impact by identifying markers for early 
detection of SCCHN, for predicting prognosis, for therapy and drug development, and aiding in 
the development of new, individualized treatment strategies.  
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1.0  INTRODUCTION 
Head and neck cancer is a broad term used to describe malignancies in the upper aero-
digestive tract, including the pharynx, oral cavity and larynx.  Although implied by “head and 
neck”, conventionally, the term does not include cancers of the brain, thyroid and melanoma (1).  
Ninety percent of head and neck cancer begins in the squamous cells that line the passages of the 
upper respiratory tract.  Named for the types of affected cells and location of the cancer, this type 
of tumor is referred to as squamous cell carcinoma of the head and neck (SCCHN) or head and 
neck squamous cell carcinoma (HNSCC).  The American Cancer Society estimates that cancer of 
the oral cavity and pharynx is the ninth most common cancer in Caucasian men and the sixth 
most common cancer in African American men, accounting for 3% of cancers in both ethnicities 
(3).  These cancers are about twice as common in men as compared to women, making them the 
14th most common cancer in women.  The lifetime risk for Caucasian males in the United States 
is approximately 1 in 72 (3).  To put this in perspective, it is estimated that about 34,360 new 
cases (24,180 in men and 10,180 in women) of cancer of the oral cavity and pharynx will be 
diagnosed in the United States in 2007.  Worldwide, the yearly incidence is expected to be 
>500,000, with the majority occurring in developing countries, including India, South Africa, 
Eastern Europe and tropical South America (1).  This makes head and neck cancer a significant 
cause of morbidity and mortality worldwide. 
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In the US, cancers of the oral cavity and pharynx are estimated to be responsible for 
approximately 7,550 deaths in 2007.  Historically, death rates have been higher in both African 
American men (1.8 times higher) and women (1.2 times higher) as compared to Caucasian men 
and women (3).  This corresponds to an average death rate of 61% in Caucasians and 40% in 
African Americans.  Although five-year survival rates have improved over time for advanced 
carcinomas of the larynx and pharynx, there has been little improvement for oral cancers or early 
laryngeal tumors.  Overall, survival is one of the lowest for the major cancers, highlighting the 
importance of studies that work to improve our understanding of the biology of SCCHN. 
SCCHN is largely preventable and positively associated with higher rates of exogenous 
risk factors including, smoking and alcohol use (1) betel nut chewing and bidi smoking in 
Southeast Asia; but, as many as 25% of cases are not attributable to these exposures (4).  A 
number of observations suggest that there may be a different mechanism of disease in non-
smokers/non-drinkers with SCCHN cases more likely to be females (73-78%) (5, 6).  In addition, 
a number of studies have reported differences in the anatomical site of tumors in smokers and 
non-smokers, with the majority of smoking-related tumors occurring in the oral cavity (5, 6).  
SCCHN has also been associated with Human Papillomavirus (HPV) with estimates of virus 
integration rates in tumors range from 21-43% (7).  Although smoking, alcohol and HPV are 
significant risk factors for SCCHN, only a fraction of people in high-risk groups will develop 
cancer.   
Head and neck cancer is thought to be a complex, heterogeneous disease involving 
multiple genetic abnormalities.  It appears that a variety of mechanisms may play a role in the 
shift to malignancy, including the inactivation of tumor suppressor genes, activation of proto-
oncogenes, promoter methylation, gene deletion, gene amplification and point mutations (8).  
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These genetic abnormalities could arise as a result of a combination exogenous factors and 
inherited susceptibility to DNA damage.  With this in mind, this study aimed to examine the 
influence of the Ataxia Telengiectasia Mutated gene (ATM) on susceptibility to SCCHN.  ATM, 
predicted to influence SCCHN, is a DNA damage response kinase that functions by 
phosphorylating key substrates involved in DNA repair and cell cycle checkpoints.  Specifically, 
a case-control based SNP association study was performed using constitutional DNA prepared 
from blood.  This work had the ultimate goal of further elucidating the etiology of SCCHN, as 
well as identifying important genetic risk factors for the disease.  
1.1 CANCER ETIOLOGY 
Cancer has been described as a ”genetic disease of the somatic cell” (9).  The formation 
of cancer can occur as a series of somatic events involving any number of possible genetic 
changes, from simple point mutations to more complex chromosomal rearrangements.  The 
common etiology of cancer consists of somatic changes, resulting in the inability of cells to 
maintain a stable genome.  Cells contain a number of safeguards to protect against somatic cell 
changes; however, a breakdown in these systems has the potential to deregulate cell growth and 
lead to malignancy. 
Throughout their lives, cells may be exposed to many different types of damage, either 
caused by endogenous or exogenous sources. When DNA damage occurs, it triggers a complex 
cascade of events and the cell responds by attempting DNA repair or inducing programmed cell 
death (apoptosis).  The attempt to repair can result in success (ie., a viable, healthy cell), 
apoptosis, or in further genomic instability and/or cancer (9).  Therefore, when studying the 
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etiology of cancer, it is important to consider the exogenous risk factors that can lead to DNA 
damage, as well as provide a discussion of DNA repair mechanisms and the endogenous factors 
that may affect this process.  
 
1.1.1 Mechanisms of DNA Repair 
Generally, the mechanisms responsible for DNA repair depend on the type of 
damage/lesion.  The Nucleotide Excision Repair pathway (NER) works to remove and replace 
bulky, DNA-distorting lesions, resulting from exposure to various environmental agents.  The 
damage is detected, DNA is unwound at the site, the nucleotide is excised and, finally, replaced 
using the opposite strand as a template (10).  The Base-Excision Repair pathway (BER) works to 
repair bases that have been modified by deamination or alkylation.  In general, these are lesions 
that do not distort the DNA backbone.  Several DNA glycosylases recognize the lesion and work 
with other proteins to repair the damaged base (10).  Double strand breaks (DSBs) can occur as a 
result of ionizing radiation (IR), chemical exposure, meiotic (or mitotic) crossing-over, a stalled 
replication fork, or immunoglobulin V(D)J recombination.  There are two main pathways for 
repairing DSBs; Non-Homologous End Joining (NHEJ), the predominant pathway in mammals, 
involves direct ligation of the two ends of broken DNA, without use of a template and can result 
in small deletions.  Homologous Recombination (HR) makes use of template DNA as a guide to 
repair and is essentially error-free (10). 
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1.1.2 Hereditary Cancer Syndromes and Related DNA Repair Defects 
Mutations in a number of genes that function in these DNA repair pathways have been 
shown to be associated with various hereditary cancer syndromes.  For example, mutations in the 
xeroderma pigmentosum (XP) gene, involved in NER, results in high UV light sensitivity and an 
increased risk for skin cancer, melanoma and other tumors (11).  In addition, NER genes are 
associated with Cockayne syndrome and trichothiodystrophy. Germline mutations in the MutY 
human homologue (MUTYH), a gene that is involved in repairing oxidative damage to DNA 
(BER pathway), and have been found to be associated with familial colorectal cancer (12).  The 
NHEJ pathway also contains genes implicated in Hereditary Breast and Ovarian Cancer 
(BRCA1/2), Fanconi Anemia (BRCA2), Li Fraumeni syndrome (TP53), Ataxia Telangiectasia 
(ATM), Bloom Syndrome (BLM) and others. 
In general, a discussion of the particulars of these gene functions and carcinogenesis 
becomes extremely complex and reveals that one gene may function in different pathways, 
interacting with multiple proteins, and performing many cellular roles (13).  Adding to this 
complexity, studies examining the levels of DNA repair pathway activity, have disagreed on 
whether an over-active or under-active pathway is associated with increased risks (14). 
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2.0  REVIEW OF THE RELEVANT LITERATURE 
2.1 EPIDEMIOLOGY OF SCCHN 
Head and neck cancer is a significant cause of morbidity and mortality worldwide with 
overall survival being one of the lowest for the major cancers.  Treatment times tend to be long 
and costly with survival rates averaging 50%.  Therefore, much work is needed to further our 
understanding of genetic and environmental risk factors, as well as the underlying biology of 
SCCHN.  This would serve several purposes, including: identifying markers for detection of 
premalignant tumors, predicting clinical outcome (prognosis), identifying targets for therapy and 
drug development, developing individualized treatments, and developing new strategies to 
predict and prevent resistance to treatment. 
 
 
2.1.1 Environmental Risk Factors 
Squamous cell carcinoma of the head and neck (SCCHN) is thought to arise due to a 
number of factors, including damage to DNA as well as deregulation of the cell cycle 
checkpoints and subsequent genomic instability.  Known environmental risk factors, and 
possible exogenous sources of DNA damage in SCCHN include:  
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1) Tobacco.  Higher risks of SCCHN are associated with smoking cigarettes, pipes, and cigars, 
and chewing tobacco (15).  About 85.4% of people with SCCHN use or have used tobacco, 
compared to 69.9% among controls (16).  Higher risks are associated with quantities 
smoked/chewed, duration and type of tobacco used.  Smokeless tobacco is especially harmful 
and increases risk by about 50 times that of a non-user (17).  
 
2) Alcohol use.  A high level of use is seen in about 75% of patients and infers a risk of oral 
cancer that is six times higher than that of non-drinkers.  The combination of both tobacco and 
alcohol use is especially harmful, with significantly increased odd ratios (OR=12.7 [95%CI = 
5.5-29.1; p-value = 0.008]) (16).  Both alcohol and tobacco have been shown to be independent 
risk factors and, together, act synergistically to increase risk (18).  Most likely this is due to the 
ability of alcohol to increase the permeability of oral mucosa to tobacco carcinogens (1, 3). 
 
3) Human papillomavirus (HPV).   Commonly seen in cervical cancers, HPV is also found in 
about 25% of head and neck cancers (19).  HPV is not necessary, nor sufficient to cause 
SCCHN, but has consistently been found more frequently in SCCHN cells than in normal 
mucosa (10%) (7).  Patients with SCCHN and an associated HPV infection appear to have a 
better prognosis and are less likely to be smokers and drinkers.  This suggests a slightly different 
disease etiology in these cases (1, 3).  Studies have also examined the relationship between 
smoking, HPV and SCCHN (20).  These researchers found that HPV seropositivity and tobacco 
appeared have an additive effect on the risk of SCCHN with an OR of 8.5 (95%CI = 5.1-14.4).  
HPV seronegative smokers had an OR of 3.2 (95%CI = 2.0-5.2) and HPV VLP-seropositive non-
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smokers had an OR of 1.7 (95%CI = 1.1-2.6).  Although studies have also disagreed in their 
findings concerning the relationship between alcohol, smoking and HPV, it appears that the 
increased risks seen in smokers/drinkers/HPV seropositive individuals is likely due to the 
additive effect of HPV and smoking (7). 
 
4) Age. The incidence of SCCHN increases with age, with the majority of cases diagnosed over 
40 years of age (1).  The association of tobacco and alcohol is well documented in older patients 
(1, 3); however, younger patients may make up a distinct subset of SCCHN cases.  Younger 
patients are more often women than men, and tumor sites are more often located on the tongue or 
in the oral cavity (21). 
 
5) Gender.  The disease is twice as common in men then in women. In both men and women, 
tobacco and alcohol use are the most striking risk factors, with men having higher rates of use 
compared to women (3, 22).  A recent study (22) analyzed data on 195 cases and 1113 controls 
from Italy and Switzerland, found slightly lower odds ratios for alcohol consumption in women 
compared to men.  The authors suggested that these lower ORs in women may represent 
underreporting of alcohol consumption or that women may be more susceptible to alcohol 
carcinogenesis.  These researchers also confirmed previous studies showing that women with 
oral cancer had lower Body Mass Indexes (BMI) than men, although this could be a consequence 
of disease rather than a cause. 
 
6) Plummer-Vinson syndrome.  A less important risk factor, Plummer-Vinson is a very rare 
syndrome with less than 30 cases reported between 1999 and 2005 (23).  The syndrome is 
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characterized by a combination of iron deficiency with abnormalities of the tongue, fingernails, 
esophagus, and red blood cells and is associated with an increased risk (3-15%) of esophageal or 
pharyngeal cancer (23).  
 
7) Ultraviolet light.  Prolonged exposure to sunlight is more common in people with cancers of 
the lip (1, 3). 
 
8) Diet.  Dietary deficiencies may be a risk factor for SCCHN in as many as 10-15% of cases, 
whereas diet is rich green vegetables, fresh fruit, B-carotene and wholegrain foods have a 
protective effect (3, 22, 24).  Increased risks of oral cancer have also been associated with greater 
intake of total fats and saturated fats (24).  
2.1.2 Genetic Risk Factors 
2.1.2.1 Tumor studies.   
Microsatellite and cytogenetic studies have suggested a model for the progression of 
SCCHN.  Specifically, an examination of SCCHN tumors reveals that they are often surrounded 
by a “field” of abnormal cells containing many genetic alterations.  In 1953, Slaughter et al. 
examined 783 cases of SCCHN and found multiple carcinomas in 11.2% of these cases.  It was 
postulated that these fields arose in areas of mucosa that had undergone prolonged exposure to 
carcinogens, causing cells to undergo numerous independent genetic changes.  This first led to 
the Slaughter et al. theory that SCCHN tumors arose from multiple primary cells (25).  More 
recent tumor studies have suggested that although the surrounding mucosa contains complex 
alterations, these changes are often related to each other and most likely arose from a “common 
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preneoplastic progenitor” (26).  These progenitor cells may migrate and expand at different sites, 
acquiring further genetic changes, which make them appear to be separate primary tumors.  As a 
result, distinguishing between a second primary tumor and a recurrence can often be difficult and 
is usually defined by the genetic similarity of the tumors (8). 
Compared to other cancers, SCCHN exhibit a very high rate of chromosomal instability 
(2) with 70% of cases showing loss of the 9p21 region.  This event is often associated with a loss 
of heterozygosity of 9p21.  This region contains genes involved in cell cycle regulation, 
including CDKN2A (8).  It is estimated that approximately 90% of SCCHN show inactivation of 
CDKN2A through deletion, promoter methylation or point mutations (27).  Also thought to occur 
early in tumor formation is the over expression of epidermal growth factor receptor, EGFR, 
(7p12).  This has been reported in approximately 90% of SCCHN and is correlated with a poor 
prognosis (28).  (Figure 1). 
 
 
 
Figure 1. Proposed mechanism for SCCHN carcinogenesis, (8). 
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Other early events in tumor formation include loss of 3p14, 3p21, 3p22, 3p24, and 3p26.  
In these regions, three candidate tumor suppressor genes have been proposed to explain these 
observations.  The fragile histidine triad gene (FHIT) (3p14) is found to be inactive in some 
SCCHN cases as well as other tumors.  RSSFIA on 3p21 is also inactive in a set of SCCHN 
tumors (8). Germline polymorphisms in the glutathione peroxidase I (GPX1) gene, on 3p21, have 
been associated with susceptibility to SCCHN (29).   
Later in tumor formation, loss of 17p13, has been observed, followed by loss of 
heterozygosity.  This region includes TP53, which responds to exogenous and endogenous 
stressors, playing a major role in the regulation of the cell cycle.  TP53 is mutated in 50-80% of 
SCCHN tumors (8, 27).  Interestingly the site of TP53 tumor mutations may be different in non-
smoking/non-drinking patients.  This may indicate that certain mutations are characteristic of 
exogenous damage, while others are characteristic of endogenous damage (30).  Although the 
stage at which TP53 loss occurs has been debated, a number of studies indicate that incidence 
increases with the shift from non-invasive to invasive cancer (31).  Although TP53 mutation is 
common in SCCHN tumors, a number of tumors form in the absence of TP53 mutations.  These 
tumors are more likely to be HPV-positive, again indicating a distinct etiology for HPV-positive 
tumor formation (8). 
About 30-76% of SCCHN tumors show loss of the distal end of chromosome 11q and 
subsequent amplification of 11q13 (32). The amplified 11q13 region contains cyclin D1 
(CCND1) and is associated with poor prognosis as well as metastatic spread to the lymph nodes. 
CCND1 is a key protein in the cell cycle, phosphorylating RB1 and enabling the transition from 
G1 to S phase (8).  Reshmi et al. have proposed that this amplification occurs as a result of 
cigarette smoke-induced double strand breaks and subsequent breakage-fusion bridge cycles in 
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chromosome 11 (33).  The original breakpoint may occur at the common fragile site, FRA11F, 
located at 11q14.  This mechanism also implies loss of the distal end of 11q, containing ATM, 
prior to the 11q13 amplification (Figure 2). 
 
 
Figure 2. Proposed mechanism for breakage-fusion-cycle in 11q amplification, (33). 
 
2.1.2.2 Molecular studies: 
Although no major SCCHN susceptibility loci have been found, many modest 
associations have been reported. 
Oncogenes: 
CCND1 is a regulatory protein, which plays an important role in the G1 to S transition in 
the cell cycle.  Mutations in the G870A splice variant lack a normally occurring 
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destruction box, causing overexpression of the protein (34).  Several studies have 
implicated polymorphisms in CCND1 with SCCHN susceptibility (35).  Zheng et al. 
suggested that the G870A splice-site AA polymorphism may contribute to early onset 
SCCHN (36).  Rydzanicz et al. found that the same AA allele was positively associated 
with higher gene expression and lymph node metastases (37).  In addition, a recent study 
of 273 cases and 269 controls found a positive association of germline variations in the 
same CCND1 allele, with higher OR’s when occuring in combination with certain 
ERCC2 (XPD) variants [OR 7.09 (95% CI 4.03 – 12.5)] (34). 
 
Tumor suppressors/DNA repair genes: 
CDKN1A (P21): regulates cell-cycle progression at the G1 phase and is controlled by 
TP53.  A significant association was found between risk of SCCHN and two 
polymorphisms (C70T and C98A).  This was a case-control study of 712 patients and 
1222 controls with OR’s approximately 1.3-1.5 for each SNP (38). 
 
XRCC1 facilitates DNA DSB and BE repair.  A large number of studies have examined 
polymorphisms in XRCC1 with differing results (39, 40). 
 
ERCC2 (XPD) is involved in the nucleotide excision repair pathway with polymorphisms 
resulting in the possible reduction of DNA repair.  Sturgis et al. reported nonsignificantly 
increased risks associated with germline polymorphisms in the ERCC2/XPD 23591A 
allele [OR 1.28 (95% CI, 0.93-1.76)] in a study of 313 cases and 313 controls (40).  Risk 
was higher in combination with the ERCC1 8092CC genotype: [OR 1.78 (95% CI, 0.99-
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3.17)].  In addition, Buch et al. showed an increased risk associated with both the 
ERCC2/XPD Asp312Asn variant [OR 1.3 (95% CI 1.0-1.8)] and ERCC2/XPD 
Lys751Gln variant [OR 2.2 (95% CI 1.5-3.2)] (34).  Also higher OR’s were observed in 
combination with the CCND1 G870A risk allele [OR 7.09 (95% CI 4.03 – 12.5)] (34).  
 
Detoxifying genes:  
Researchers have examined the role of interindividual genetic differences in modifying 
the risks of alcohol and tobacco exposure (18, 41) and found that variations in enzymes 
responsible for metabolism of carcinogens may be associated with SCCHN risk. 
 
GST’s (Glutathione S-transferases) make up a family of enzymes involved with 
detoxifying tobacco smoke.  Over 20 studies have focused on variations in the GSTM1 
variations in SCCHN patients with OR’s ranging from nonsignificant to OR’s of 3.9 (42). 
A recent study (692 cases, 753 controls) examined the synergy of GST genes with 
tobacco and smoking exposure (18).  The researchers found that individuals who were 
homozygous for deletions in the GSTM1 gene and who were heavy-drinkers and heavy-
smokers, had significantly increased risks to develop SCCHN (OR, 12.6; 95% CI, 4.0-
40.2).  These individuals have a complete lack of enzyme function and are thought to 
have a reduced ability to detoxify carcinogens. 
 
SULT1A1: Mutations in sulfotransferase (SULT) 1A1, also a detoxifying agent, have been 
found to be associated with SCCHN (OR=3.60; 95% CI=1.01-12.88) in older people who 
had high alcohol and low fruit intake (43). 
 15 
 
ADH1C (alcohol dehydrogenase 1C) is known to play a role in the elimination of alcohol 
from the body.  Peters et al. investigated ADH1C genotypes in 521 cases and 599 controls 
from the Boston area.  They found a significant increase in cancer risk in those heavy 
alcohol users who were ADH1C homozygote variants: OR of 7.1 (95% CI, 2.3-22.0) (44).  
 
Nutrient metabolism genes:  
MTR (Methionine Synthase) and MTRR (Methionine Synthase Reductase) in the folate 
metabolic pathway have been associated with moderate changes in susceptibility to 
SCCHN, although confirmatory studies are needed (45). 
 
MTHFR (Methylenetetrahydrofolate Reductase):  Variations in the MTHFR gene have 
been shown to influence folate metabolism.  Three polymorphisms have been shown to 
be associated with increased risk to SCCHN.  Neumann et al. genotyped the C677T, 
A1298C and G1793A alleles in cases and controls and found OR’s = 1.85 (1.3-2.5) for 
any 2 risk alleles and OR = 1.93 (1.4-2.7) for any three risk alleles (46). 
 
TYMS (Thymidylate Synthase) also known to be involved in folate metabolism was 
examined by Zhang et al.  The group found a number of polymorphisms which were 
protective or associated with decreased stage of cancer (47). 
 
GPX1 (Glutathione peroxidase I) codes for a selenium-dependent enzyme that helps to 
protect cells against oxidative damage.  Located in the 3p21 region (frequently lost in 
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SCCHN tumors), polymorphisms in GPX1 have been associated with SCCHN (OR=1.6) 
(29).  It should be noted that this study was limited by small sample sizes as well as lack 
of smoking/alcohol status. 
 
VDR (Vitamin D Receptor):  Liu et al. showed that polymorphisms in the VDR gene may 
alter risk to SCCHN.  The examined two polymorphisms (FokI and TaqI restriction site 
polymorphisms) in 719 cases and 821 controls and found that homozygous variant 
genotypes for both were associated with decreased risk for SCCHN (ORs between 0.64 
and 0.72) (48). 
Other: 
IL4 (interleukin 4) is a cytokine produced by activated T-cells.  Vairaktaris et al. 
examined 156 cases and 162 controls and recently reported an association of the (IL4) C-
590>T polymorphism and increased risk for oral squamous cell carcinoma (OSCC) (49).  
The association was significant in early stages of this malignancy (P < .0001; OR 3.17, 
95% CI 1.31-7.65).  The authors propose that IL4 has a growth-promoting effect and 
show that this polymorphism increases expression of the gene. 
 
Response to chemotherapy:  
Studies have examined the relationship between SNPs in DNA repair genes and response 
to cisplatin, which kills cells by DNA crosslinking (50).  The researchers analyzed four 
SNPs, ERCC2 (XPD)-Asp312Asn, ERCC2 (XPD)-Lys751Gln, ERCC1-C8092A, and 
XRCC1-Arg399Gln, in peripheral lymphocytes DNA from 103 stage IV SCCHN 
patients.  They found a significant association between survival and polymorphic 
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variants.  This work had built on previous findings of similar effects of these SNPs in 
non-small-cell lung cancer (51) and highlights the possibility of individualized 
chemotherapy regimens based on genotype. 
2.2 ATM AND DNA REPAIR 
Genes in regions implicated in tumor progression (Figure 1) may provide targets for 
susceptibility studies.  Knudsen’s two-hit hypothesis states that dominantly inherited cancers 
occur as a result of two mutation events that work to decrease or eliminate gene function.  The 
first mutational event or “first hit” may occur as an inherited mutation, effectively increasing 
susceptibility to tumors.  The second hit may occur somatically, resulting in cancer formation 
(52).  It follows that if expression changes in genes are related to SCCHN progression, germline 
mutations in these genes may predispose an individual to carcinogenesis by providing the “first 
hit” in somatic cells.  A second hit could then occur by endogenous or exogenous DNA damage, 
causing complete loss of heterozygosity.  This is believed to be the mechanism for cancer 
development in a number of autosomal dominant cancer syndromes, including hereditary breast 
and ovarian cancer, where loss of heterozygosity of the BRCA1 or BRCA2 tumor suppressor 
function causes the observed cancers.  Similarly, loss of ATM in tumors has been associated 
with carcinogenesis, and it is theoretically possible that germline mutations could increase 
susceptibility to SCCHN. 
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2.2.1 Function of ATM 
Double strand breaks in DNA can occur as a result of exogenous factors such as 
ionization radiation (IR) or common endogenous activities such as recombination and the 
nucleotide excision repair pathway (53).  In response to double strand DNA breaks (DSBs), the 
cell utilizes a number of proteins that sense the damage (sensors), transducers that amplify this 
signal and effectors that induce the response and repair (Figure 3).  
 
Figure 3. Model of DNA double-strand-break response pathway, (53). 
 
 
These pathways are not completely understood, but it is clear that members of the PI3 
kinase-related kinases (PI3KKs) play a role in the initial response.  The most important PI3KKs 
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involved in the damage response are: Ataxia Telangiectasia Mutated (ATM) and Rad3 related 
(ATR).  These kinases respond to double strand breaks by phosphorylating other key proteins 
involved with cell cycle control and DNA damage repair.  In general, ATM responds in the G1 
phase in response to IR-induced DSBs, while ATR function predominates in S/G2 phase in 
response to replication-associated DSBs or stalled replication forks.  ATM interacts with a large 
number of other proteins such as checkpoint factors (CHEK’s), tumor suppressors (TP53, 
BRCA1), DNA repair factors (RAD50, RAD51, GADD45) and other signaling molecules (ABL1, 
NFKB1) (Figure 4). 
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Figure 4. The ATM signaling pathway, (53, 54). 
 
 
This response can be broken down into the primary and secondary phases.  In the primary 
response, sensor proteins detect DNA double strand breaks, transducer and adaptor proteins 
recruit effector proteins and repair occurs by NHEJ or homologous recombination (HR).  A 
secondary response occurs when DSB’s are abundant and severe.  This results in delays in cell 
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cycle, transcription of certain genes, recruitment of other DNA repair proteins and if 
unsuccessful, apoptosis (53). 
The ATM and ATR kinases appear to respond to damage both as primary sensors and as 
secondary transducers of the response signal.  In the sensor capacity, ATM and ATR cooperate 
with MRN to phosphorylate H2AFX.  H2AFX, in turn, functions to recruit a large DNA 
repairisome, including BRCA1 to the site of damage (53).  As transducers, ATM and ATR initiate 
a phosphorylation cascade through BRCA1, effecting TP53, NBN (NBS1) and CHEK2.  This 
results in the initiation of cell cycle checkpoints and a delay in cell cycle progression (Figure 5).  
 
 
 
Figure 5. Model of DNA double-strand-break response genes, (53). 
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2.2.2 ATM and Disease 
The ATM gene was first identified as the genetic cause of ataxia-telangiectasia (AT) in 
1995 (55).  The ATM gene is located at 11q22.3 and consists of 66 exons and is approximately 
3Kb in length.  Over 300 AT-causing mutations have been reported in the ATM gene all of which 
are either missense, nonsense, splicing or truncating mutations; the truncated proteins are almost 
completely inactive (56).  AT is an autosomal recessive genomic instability disorder, resulting 
from an inability of cells to respond to double strand breaks.  The disease is characterized by 
sensitivity to ionizing radiation and DSB-inducing agents, severe and progressive neuromotor 
dysfunction, immunodeficiency, genomic instability, and a predisposition to non-Hodgkin’s 
lymphoma (40%), acute lymphocytic leukemia (20%) and Hodgkin’s lymphoma (5%) (9, 57) in 
young adults and epithelial cancers (eg. breast cancer) in adults.  Most people with AT are 
compound heterozygotes, but occasionally, homozygotes have been observed.   Although AT is a 
rare disease (1 in 40,000), it is estimated that AT heterozygote frequency might fall between 
0.68% and 7.7%, with 2.8% being a likely estimate (58).  Therefore, even a modest increase in 
cancer risks associated with AT carrier status would have a significant public health impact.  As 
a result, an intensive effort has been made to determine what risks are associated with AT 
heterozygosity.  
2.2.2.1 ATM and breast cancer. 
An association between AT heterozygotes and breast cancer, based on epidemiological 
evidence, was first reported 20 years ago (59).  This study was based on AT families and 
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calculated the relative risk for (any) cancer to be 2.3 for men and 3.1 for women.  When 
stratified for cancer type, the highest significance was found for breast cancer.  Since then, a 
number of studies have attempted to confirm this epidemiological finding as well as identify 
ATM polymorphisms associated with increased risk for breast cancer.  A recent epidemiological 
study by Thompson et al. (60) characterized the cancers observed in the relatives of AT patients 
(Table 1) and found the overall RR for breast cancer to be 2.23 overall and higher in women 
under 50 years old (RR=4.9). 
 
 
 
Table 1. Cancer incidence in 1160 relatives of 132 AT patients, (60). 
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In general, studies whose design involved case/control screening for ATM variants in a 
breast cancer population have failed to show an association with breast cancer risk (61).  This 
may be a result of small study size, screening modalities that were more likely to detect 
truncating mutations (rather than missense mutations), an inability to control for BRCA1/2 status, 
or a focus on sporadic rather than familial cases (61).  One recent study overcame these 
difficulties by studying BRCA-negative familial breast cancer cases and controls and screening 
the entire ATM gene.  The group found that the relative risk of breast cancer associated with 
ATM mutations was estimated to be 2.37 (95% CI = 1.51–3.78, P = 0.0003), which agrees with 
previous epidemiological findings (56).  Another study of similar design focused on a population 
of high-risk, non-Ashkenazi Jewish women who tested negative for BRCA1/2 (61).  The group 
found a significant association between one ATM SNP (rs228589) and risk for breast cancer OR 
=12.61 (95% CI =5.91 – 26.92, P = 4 X 10-9).  Additionally, other ATM alterations that have 
been found to be associated with breast cancer include: Val2424Gly (associated with increased 
risk of breast cancer in AT families) (62), and IVS10-6T>G (associated with early onset breast 
cancer) (63).  Teraoka et al. examined the mutation type and found an association between 
missense mutations and breast cancer risk but with no association between truncating mutations 
and risk (64).  This finding was supported by Dork et al. (65), but not in Thompson et al. (60).  
This leads to the possibility of two distinct ATM mutation types that confer different risks, 
however, more studies are needed to confirm this observation. 
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2.2.2.2 ATM and lung cancer 
An association between ATM and lung cancer was first reported in a case-control study of 
616 Korean lung cancer patients and 616 controls (66).  This study also used a tag-SNP approach 
to select SNPs of interest and found an association between the IVS62 +60G>A (rs664143) 
allele and lung cancer risk [odds ratio = 1.6, 95% confidence interval (CI) 1.1–2.1].  Following 
haplotype analysis, they found and association between the ATTA haplotype at sites -4518A>G 
(rs189037), IVS21 -77C>T (rs664677), IVS61 -55T>C (rs664982) and IVS62 +60G>A 
(rs664143), and increased risk of lung cancer (OR = 7.6, 95% CI 1.7–33.5).  Additionally, the 
(NN)TA haplotype was associated with a highly significant increased risk of lung cancer  (OR = 
13.2, 95% CI 3.1–56.1).   
Landi et al. examined a different set of 4 ATM SNPs in a recent case-control study from 
Central and Eastern Europe.  They found an association between the IVS48+238 C>G alteration 
(rs609429) and decreased risk for lung cancer (OR = 0.55, CI = 0.30-0.98, P = 0.03) (67). 
2.2.2.3 ATM and squamous cell carcinoma of the head and neck (SCCHN) 
A number of studies have shown loss of heterozygosity (LOH) in the 11q22-23 region 
(68-73) in SCCHN tumors. Lazar et al. found that 25% of SCCHN tumors showed LOH at 
11q23 and upon follow-up, found that LOH in this region was associated with persistent or 
recurrent disease in patients receiving radiotherapy (RT).  They suggest that this may indicate a 
resistance to RT, related to genes in this region (68).  These findings have lead to efforts to 
examine possible mechanisms related to this observation. 
Although it is unclear if ATM is lost in the above studies, it is located in or near the 
regions described and is therefore a candidate for further studies.  Lingbao et al. built on previous 
work that demonstrated that hypermethylation ATM promoter results in reduced expression of 
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the gene.  When examining ATM methylation in SCCHN, the group showed that approximately 
25% of cases showed aberrant methylation and that this was associated with decreased overall 
patient survival (74).  
As far as we know, this is the first study to examine germline mutations in ATM in 
patients with SCCHN.  
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3.0  METHODS 
Research subjects were previously recruited as part of the Head and Neck SPORE and the 
Oral Cancer study at the University of Pittsburgh.  Specifically, cases were individuals diagnosed 
with primary SCCHN within one year of enrollment of the study.  Cases could have a history of 
another primary tumor but controls did not have any personal history of cancer, regardless of 
type.  Controls were recruited from community settings and clinical settings (patients of the 
UPMC ENT Clinic or University of Pittsburgh Dental School).  The racial, gender, and ethnic 
characteristics of the proposed subject population reflect the demographics of Pittsburgh and the 
surrounding area and/or the subject population of the University of Pittsburgh Medical Center.  
No exclusion criteria were based on race, ethnicity, gender, or HIV status. 
3.1.1 Subject Recruitment 
At the University of Pittsburgh Medical Center Ear, Nose and Throat Clinic and 
University of Pittsburgh Cancer Institute Hematology/Oncology Clinics, potential case and 
control research subjects were first identified by their primary care physician or clinical care 
team.  If the patient had signed the Ear, Nose and Throat (ENT) Patient Data Registry (IRB # 
010356), the subject was identified by a study coordinator.  The research project was then 
discussed with the patient to assess interest in participation.  If interested, the caregiver instructed 
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the patient to either contact the research team directly for additional information; or, if the patient 
had not signed the ENT Patient Data Registry, he/she was provided an IRB approved written 
Authorization for the Sharing of Health Information Related to Possible Participation in a 
Research Study.  This allowed the caregiver to inform the researcher of the patient’s interest, 
share health information (related to study inclusion), and allowed the involved researchers to 
contact the patient for additional discussion related to participation. The Clinical Research 
Coordinators conducted the verbal screening process and obtained written informed consent for 
potential case subjects, prior to the blood draw and interview. 
At the University of Pittsburgh Dental School, Dental School students informed their 
patients of the research study and, if interested, the potential subject was directed to the location 
of the research team in the clinic.  The research team conducted a verbal screening to determine 
eligibility and interest.  If interested in participation, the researcher obtained written informed 
consent, obtained a blood sample, and conducted an interview. 
 
3.1.2 Inclusion and Exclusion Criteria 
Inclusion criteria (cases): 
• Age 18-79 years on date of first diagnosis of qualifying head and neck cancer. 
• Biopsy proven primary squamous cell cancer at a head and neck site.  For the purposes of 
this research, head and neck cancer sites include primary tumors coding to Chapter 3 (Lip 
and Oral Cavity), Chapter 4 (Pharynx, including base of tongue, soft palate, and uvula), 
Chapter 5 (Larynx), or Chapter 6 (Nasal Cavity and Paranasal Sinuses) of the AJCC 
Cancer Staging Manual (6th edition). 
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• Study enrollment (acquisition of informed consent and collection of questionnaire data) 
on or before the one-year anniversary of the first diagnosis of the qualifying head and 
neck cancer. 
 
Exclusion criteria (cases): 
• Age less than 18 years on date of first diagnosis of qualifying head and neck cancer. 
• Age more than 79 years on date of first diagnosis of qualifying head and neck cancer. 
• Absence of a clinical pathology report documenting invasive cancer involving a head and 
neck site. 
• Histopathologic diagnosis other than squamous cell carcinoma.  Diagnoses were subject 
to verification by a Pathologist. The investigators removed a participant from this 
research study if the final pathology report did not confirm the provisional diagnosis used 
for study enrollment purposes.  If the final pathology report did not demonstrate primary 
squamous cell carcinoma of the head and neck, the investigators removed the participant 
from the study and his/her data and blood sample was rendered anonymous and 
destroyed. 
• More than one year elapsed time since date of first biopsy diagnosis of most recent 
primary squamous cell carcinoma at a head and neck cancer site.   
 
Inclusion criteria (controls): 
In order to be included the study, controls needed to meet the following inclusion criteria: 
• Age: 18-80 years old on date of enrollment. 
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• Cancer history: No personal history of cancer at a head and neck site (based on eligibility 
screening interview and/or review of ENT or Dental Clinic medical record). 
• Clinical examination (clinic controls): Clinical examination (by personal ENT physician 
or dentist), without clinical suspicion of head and neck cancer, based on testimony of 
clinician or review of primary medical records. 
• County of residence (If a neighborhood control): Residence in Allegheny (including 
greater Pittsburgh), Butler, Green, Cambria, Jefferson, Fayette, Westmoreland, 
Washington, Beaver, Lawrence, Mercer, Crawford, Erie, Venango, Clarion, Armstrong, 
or Indiana county (in Pennsylvania); Jefferson (including Steubenville), Columbiana, or 
Mahoning (including Youngstown) county (in Ohio); or Ohio (including Wheeling), 
Brook, or Hancock county (in West Virginia). 
 
Exclusion criteria (controls): 
Controls were excluded from the study if they met any of the following criteria: 
• Age less than 18 years or more than 80 years on date of enrollment. 
• Self-report of personal history of cancer at a head and neck cancer site. 
• (If a clinic control) Indication in ENT or dental clinic record of personal history of cancer 
at a head and neck cancer site. 
• (If a clinic control) Physical findings, on head and neck clinical examination, that creates 
a suspicion of cancer at a head and neck cancer site. 
• (If a neighborhood control) Residence in a location other than Allegheny (including 
greater Pittsburgh), Butler, Green, Cambria, Jefferson, Fayette, Westmoreland, 
Washington, Beaver, Lawrence, Mercer, Crawford, Erie, Venango, Clarion, Armstrong, 
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or Indiana county (in Pennsylvania); Jefferson (including Steubenville), Columbiana, or 
Mahoning (including Youngstown) county (in Ohio); or Ohio (including Wheeling), 
Brook, or Hancock county (in West Virginia). 
3.1.3 Epidemiological variables 
For the purposes of this study, the epidemiological variables collected were: age, gender, 
race (Caucasian or African American), family history of cancer (yes, no), and height and weight 
(BMI was calculated), smoking history (yes = at least one cigarette a day for six months or 
longer, no), alcohol consumption (yes = one or more drinks per month for one year or longer, no) 
and household smoking (yes = until the age of 18, your father, mother, or anyone else in your 
household smoked cigarettes, no), pack-years (number of years smoking history, multiplied by 
the number of cigarettes/day divided by 20).  
3.1.4 Sample Processing 
For both the OCC and HN-SPORE sample sets, whole blood was drawn into purple top 
EDTA vacutainer tubes and promptly frozen at -80 degrees C.  
Oral Cancer Center samples: 
This sample set was originally delivered to Dr. Robert Ferrell’s lab at the University of 
Pittsburgh for genotyping, related to previous genotyping studies.  Technicians in Dr. Marjorie 
Romkes’ lab at the University of Pittsburgh had previously extracted the DNA using the Gentra 
System, Inc. (Minneapolis, MN, USA) Puregene® kit.  When delivered to the Ferrell lab, these 
samples had initially performed poorly in a PCR reaction and were re-extracted (in Dr. Ferrell’s 
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lab) using the Qiagen (Valencia, CA, USA) QIAamp DNA Blood Mini Kit.  Following this 
second extraction, sample performances were greatly improved.  Due to limited resources, the 
samples were whole-genome amplified by technicians in Dr. Ferrell’s lab using the 
GenomiPhiTM DNA Amplification Kit by GE Healthcare (Piscataway, NJ, USA).  These 
samples were further diluted to a final concentration of 1:1000 for PCR use. 
 
HN-SPORE samples: 
Technicians in Dr. Marjorie Romkes’ lab at the University of Pittsburgh had previously 
extracted the DNA using the Gentra System, Inc. (Minneapolis, MN, USA) Puregene® kit.  The 
samples were delivered directly to Dr. Susanne Gollin’s lab and tested for PCR performance.  
Following successful amplification, samples were whole-genome amplified using the Qiagen 
(Valencia, CA, USA) Repli-g kit.  Again, performance was tested and samples were diluted to 
optimal concentrations for PCR, depending on sample quality. 
3.1.5 Identification of the SNP Set 
 Currently, a query in dbSNP (build 127), a part of the National Center of Bioinformatics 
Institute, returns over 800 publicly reported SNPs in the ATM gene.  Due to limited resources, 
sequencing or genotyping of all SNPs was not possible.  With this in mind, it is advisable to take 
advantage of known regions of linkage (haplotypes) within a gene to avoid redundancy in 
genotyping and to identify a subset of informative SNPs.  This idea stems from the fact that 
individual alleles physically located near each other in a gene are often inherited together.  This 
means that often there is also a correlation between genotypes at one SNP allele and its 
neighboring SNP allele.  Genotyping SNPs that mark known haplotypes (tagSNPs) can allow 
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inference of SNP genotypes at other sites in the linkage block.  This correlation is referred to as 
Linkage Disequalibrium (LD).  The combination of alleles along a chromosome is described as a 
haplotype.  
The publicly available data and software from the International HapMap project has 
made it possible to search for tagSNPs.  The project was launched in 2002 to “create a public 
database of common human sequence variation, providing information to guide genetic studies 
of clinical phenotypes” (75).  Tagger (Haploview), a tool for selection of tagSNPs, was created 
by Paul de Bakker in the labs of David Altshuler and Mark Daly at the Center for Human 
Genetic Research of Massachusetts General Hospital and Harvard Medical School, and the 
Broad Institute for the HapMap project.  The tool is publicly available and described in (76) 
“Efficiency and power in Genetic Association Studies”.  This software allows the researcher to 
query the HapMap data based on a number of variables: 
 
Ethnicity:  HapMap data were collected from four populations, the Yorubas in Nigeria, Japanese, 
Han Chinese and U.S. residents with ancestry from northern and western Europe (CEU).  
Because LD occurs due to shared ancestry, haplotypes vary between these populations.  For the 
purpose of this study, the data queries were restricted to “CEU” which most closely matches the 
ethnic background of our patient population. 
 
Statistical TagSNP-Picking Method:  The software allows tags to be picked using either a 
pairwise or multimarker method.   Descriptions of these two methods can be found in de Bakker 
et al. (76).  Multimarker methods aggressively search for a haplotype of tags that can be used to 
infer other SNPs.  This method decreases the overall number of tagSNPs needed (as compared to 
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the pairwise method) while maintaining power.  Therefore, multimarker tag picking was used for 
tagSNP-picking.   
 
Coefficient of Determination: The Tagger software also lets users pick a minimal coefficient of 
determination (r2) at which all alleles are to be captured.  By default, this was set to 0.8.   
 
Minimum Allele Frequency:  The minimum allele frequency allows the researcher specify a 
minimum minor allele frequency to be considered by the algorithm.  The minimum allele 
frequency was set to 5% due to power limitations at lower allele frequencies.  
 
Using these settings, a total number of eleven tag SNPs were picked for the initial 
genotyping. These tag SNPs were supplemented with one additional SNP, predicted to function 
as a splice-site.  Two rounds of genotyping were necessary to obtain nine functional tag SNP 
assays and one splice-site assay (Table 2, Figure 6).  Two tag SNP assays failed repeatedly and 
no suitable replacement assay was available.  In total, the nine tag SNPs captured 60 of 64 ATM 
alleles (with a frequency over 5%).  The mean R2 was 0.998 with the lowest R2 being 0.891.  
 
 
 
 
 
 35 
 
Table 2. Genotyped SNPs. 
 
 
 
 
Figure 6. Genotyped SNPs relative to the ATM gene. Adapted from the ATM gene model by the Seattle 
Mouse Comparative Genomics Center (77)  
ATM SNP SNP location dbSNP Position SNP type Alias
rs4987886 Intron 1 11658469 Tag
rs4987889 Intron 1 11658701 Tag
rs228591 Intron 1 11659749 Tag
rs11212570 Intron 16 11693128 Tag
rs3092991 Intron 18 11702932 Tag
rs1800889 Exon 30 11725903 Tag Pro1526Pro
rs611646 Intron 37 11739513 Tag
rs17503908 Intron 57 11777813 Tag
rs373759 Intron 59 11783073 Tag
rs17174393 Intron 60 11787024 Splice site
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3.1.6 Genotyping 
TaqMan® SNP Genotyping Assays were purchased from Applied Biosystems (Foster 
City, CA, USA).  The TaqMan® genotyping assays are based on real-time PCR technology, 
using allele-specific probes and primers.  The probes are labeled with either VIC or FAM dye 
and selectively anneal to the corresponding DNA sequence (SNP).  The detection is made 
possible by exonuclease activity of the Taq polymerase and the cleavage of the dye-label.  
Following the arraying of DNAs in 96-well plate format, the plates and assays were delivered to 
the University of Pittsburgh Genomics and Proteomics Core Laboratory (GPCL) for genotyping.  
The 96-well DNA plates were then rearrayed into a 384-well plate format.  PCR was performed 
according to Applied Biosystems specifications using the Applied Biosystems 7900HT 
instrument. (AppliedBiosystems.com) 
 
Each well contained: 
2.5uL TaqMan® Universal PCR Master Mix (2 ), No AmpErase® UNG  
0.25uL SNP Genotyping Assay Mix (20 )  
2.25uL sample DNA (diluted 1:20 in nuclease-free water) 
5uL Total 
 
One “No Template Control” (NTC) containing TE or Nuclease-free water was added by 
the GPCL to the last well of each plate.  The PCR profile used was: Hold 2 minutes at 50 degrees 
C, hold for 10 minutes at 95 degrees C, followed by 40 cycles of: 15 second hold at 95 degrees C 
and hold 1 minute at 60 degrees C. 
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Results were returned from the GPCL as .SDS files, which contain all raw fluorescent 
values.  Due to data quality concerns, the raw spectral data were analyzed in two separate ways 
and all statistical analyses were performed on both types of analyses.  First, genotype calls were 
made by hand, by calling according to cluster.  In some SNPs, there was concern that about the 
accuracy of these genotype calls.  Therefore, a second, non-standard method was developed to 
supplement these calls.  This method consisted of converting the raw allele X and allele Y 
spectral data to a single value, approximating the slope from the origin (relative to each SNP).  
This was done using the following formula where Y= the raw Y fluorescence value for a 
particular data point (representing the Y allele), and X= raw X fluorescence for a particular data 
point (representing the X allele):  Y/(X+Y).  To adjust for background (different points of origin 
for each SNP) the working equation became: (Y-Ymin)/[(X-Xmin) + (Y-Ymin)] where Ymin 
and X min represented the lowest value observed for each axis.   
Blinded quadruplicate positive control samples of (unknown genotype) were included for 
each assay to insure proper genotype assignment and data integrity. Three to four positive 
controls of known genotype were included per 384-well plate.  These were samples from the 
CEPH collection and ordered through the National Institute of General Medical Sciences 
(NIGMS).  Researchers were blinded to case-control status until data were generated and 
genotype calls were made.  All SOPs regarding laboratory safety were followed as well as 
separation of pre and post-PCR products to avoid contamination.  
3.1.7 Statistical Analysis 
Allele frequencies were calculated for both cases and controls and goodness of fit to the 
expected Hardy-Weinberg frequencies was measured in controls.  The χ2 test was used to 
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examine genetic differences between cases and controls and P-values were generated for each 
SNP. The χ2 test was also used to examine the significance of each epidemiological risk factor 
(perceived to play a role in SCCHN based on the literature or the biology of the disease) relative 
to case-control status.  For continuous variables “age” and “pack-years of smoking”, data were 
binned according to the mean value of the controls.  Body mass index (BMI) was binned into 
biologically relevant categories (<18.5, 18.6-25, 25.1-30, and >30 kg/m2) and not according to 
means. For those variables that were found to be significant, a logistic regression model was 
created to test for SNP significance, controlling for these factors.   The significant factors 
included in the regression model were: age (as a continuous variable), sex, pack-years 
(continuous; included instead of smoking history), alcohol history and BMI (as a continuous 
variable).  This binary logistic regression model was used to test for disease associations in both 
result sets: genotype calls and the calculated slope value.  In summary, the data were examined 
in a number of ways: genotype calls were examined for their association with case/control status, 
in a logistic regression (unadjusted and adjusted).  The slope-calculation was also examined in a 
logistic regression (unadjusted and adjusted).  All analyses were carried out using the SPSS 
statistical 15.0 software. 
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4.0  RESULTS 
4.1.1 Epidemiological variables and SCCHN risk 
Of the major epidemiological variables examined in the study, those found to be 
associated with case/control status were: sex [OR=1.7, (CI: 1.2-2.3)], with the higher risk in 
males; positive smoking history [OR=1.5 (CI: 1.02-2.1)]; pack-years [OR=2.3 (CI: 1.7-3.2)], 
with the highest risk in those who reported >20 pack-years; alcohol use [OR=2.0 (CI: 1.2-3.3)], 
with the higher risk in drinkers; and BMI of 18.6-25.0 [OR=1.7 (CI: 1.24-2.38) (Table 3).    
 
 
Table  3. Epidemiological variables. 
Variables Case (N=300) Control (N=360) OR 95% CI
Age: >57 161 (52.8) 180 (49.9) 1.1 0.8-1.5
Sex (number male) (%) 232 (76.1) 237 (65.7) 1.7 1.2-2.3
Race: number caucasian (%) 302 (99) 358 (99.2) 0.8 0.2-4.2
History of cigarette smoking: 
number "yes" (%) 237 (78.5) 257 (71.4) 1.5 1.0-2.1
Packyears: >20 185 (61.7) 148 (41.1) 2.3 1.7-3.2
Household cigarette use: 
number "yes" (%) 223 (74.6) 248 (68.7) 1.3 0.9-1.9
Family history of cancer: 
number "yes" (%) 180 (59.8) 208 (57.8) 1.1 0.8-1.5
Alcohol use: number "yes" (% 278 (91.7) 305 (84.7) 2.0 1.2-3.3
BMI (kg/m2):                  </=18.5 11 (3.7) 7 (1.9) 1.9 0.74-5.03
18.6-25.0 119 (39.8) 100 (27.8) 1.7 1.24-2.38
25.1-30.0 99 (33.1) 147 (40.8) 0.7 0.52-0.99
>30 70 (23.4) 106 (29.4) 0.7 0.52-1.04
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The means of continuous variables were calculated in cases and controls.  The mean age of the 
controls was 57.1 years and 58.0 years in cases.  The mean BMI in controls was 27.8 compared 
to a mean BMI of 26.7 in cases.  The mean pack-years smoked in controls was 20.5 compared to 
37.5 pack-years in cases (Table 4).  
 
Table 4. Epidemiological variables. 
 
 
 
4.1.2 Association of ATM SNPs and SCCHN risk 
Of a total of 300 cases and 360 controls genotyped for 10 ATM SNPs, the genotyping success 
rate ranged between 79 and 94% for all SNPs with a mean success rate of 89%.  Each SNP was 
examined for deviations from Hardy-Weinberg and all controls were found to be in Hardy-
Weinberg equilibrium.  Allele frequencies and P-values for SCCHN cases and controls for each 
of the ten SNPs are shown in Table 5.  Significant differences in genotype frequencies were 
observed between SCCHN cases and controls for rs611646 (P = 0.012) and rs373759 (P = 
0.025).  For rs611646, the TT genotype was more common in cases than controls (45 versus 
32%) while the AA and AT genotypes were less common in cases than controls (18 versus 21% 
and 37 versus 46%, respectively).  In SNP rs373759, the CC genotype was more common in 
Variables Case (N=300) Control (N=360)
Age (mean+/- SD) (years) 58.0 +/- 10.5 57.1 +/- 11.5
BMI (mean+/- SD) (kg/m2) 26.7 +/- 6.1 27.8 +/- 5.2
Packyears (mean =/- SD) 37.5 +/- 35.9 20.5 +/- 23.8
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cases than controls (56 versus 48%) with the CT type being less common in cases than controls 
(29 versus 40%).   
 
Table 5. Allele frequencies. 
 
SNP Total P-value
Intron 1 (rs4987886) AA AT TT A T
SCCHN cases 279 253 (90.7) 24 (8.6) 2 (0.7) 0.95 0.05
Controls 322 305 (94.7) 16 (5.0) 1 (0.3) 0.97 0.03 0.156
Intron 1(rs4987889) CC CT TT C T
SCCHN cases 279 269 (96.4) 10 (3.6) 0 (0) 0.98 0.02
Controls 328 317 (96.6) 11 (3.4) 0 (0) 0.98 0.02 0.877
Intron 1(rs228591) AA AG GG A G
SCCHN cases 272 66 (24.3) 113 (41.5) 93 (34.2) 0.45 0.55
Controls 310 64 (20.6) 136 (43.9) 110 (35.5) 0.43 0.57 0.576
Intron 16 (rs11212570) AA AG GG A G
SCCHN cases 261 6 (2.3) 37 (14.2) 218 (83.5) 0.09 0.91
Controls 316 6 (1.9) 46 (14.6) 264 (83.5) 0.09 0.91 0.94
Intron 18 (rs3092991) AA AG GG A G
SCCHN cases 269 199 (74.0) 62 (23.0) 8 (3.0) 0.86 0.14
Controls 289 228 (78.9) 53 (18.3) 8 (2.8) 0.88 0.12 0.375
Exon 30 (rs1800889) CC CT TT C T
SCCHN cases 284 257 (90.5) 27 (9.5) 0 (0) 0.95 0.05
Controls 328 294 (89.6) 34 (10.4) 0 (0) 0.95 0.05 0.724
Intron 37 (rs611646) AA AT TT A T
SCCHN cases 250 44 (17.6) 93 (37.2) 113 (45.2) 0.36 0.64
Controls 279 59 (21.1) 129 (46.2) 91 (32.6) 0.44 0.56 0.012
Intron 57 (rs17503908) GG GT TT G T
SCCHN cases 286 3 (1.0) 42 (14.7) 241 (84.3) 0.08 0.92
Controls 342 3 (0.9) 60 (17.5) 279 (81.6) 0.10 0.90 0.616
Intron 59 (rs373759) CC CT TT C T
SCCHN cases 266 149 (56.0) 77 (28.9) 40 (15.0) 0.70 0.30
Controls 320 152 (47.5) 127 (39.7) 41 (12.8) 0.67 0.33 0.025
Intron 60 (rs17174393) AA AG GG A G
SCCHN cases 290 0 (0) 3 (1.0) 287 (99.0) 0.01 0.99
Controls 336 0 (0) 6 (1.8) 330 (98.2) 0.01 0.99 0.431
Allele FrequencyGenotype (%)
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A logistic regression analysis was performed for each SNP with and without covariates: 
sex, BMI, alcohol, and pack-years.  Although smoking history was significantly related to 
case/control status, pack-years was used in the model because it is a more specific measure of 
smoking.  The logistic regression included one ATM SNP at a time and separate analyses were 
performed for genotype calls and the slope-calculation. There were no significant differences 
between the adjusted and unadjusted regression analyses; adjusted data are shown in Tables 6 
and 7.   SNP rs611646 remained significant when adjusted for risk factors in both the genotype 
call analysis [OR = 1.38, (CI: 1.07-1.77] and the slope-calculation analysis [OR= 4.04, (CI: 1.53-
10.67)].  SNP rs373759 appeared to be significant when examined before logistic regression, but 
not after the regression analysis.  This can be explained by the apparent over-dominant effect 
observed in this SNP.   The logistic regression, which codes the genotypes as 0, 1, and 2 is 
specifically looking for a linear effect in the data.  
Rs3092991, on the other hand, was only found to be associated with SCCHN in the 
slope-calculation analysis.  Theoretically, this could be explained by any unexpected grouping of 
cases or controls within genotype clusters, which would cause the slope-calculation to perceive 
differences within genotype groups.  To test this hypothesis, case/control status was graphed 
along with raw data reads (Figure 7).  There were no obvious visual differences within genotype 
clusters.  Further examination of the genotype data is needed to explain the difference in 
significance observed in these two analyses. 
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Table 6. Sex, BMI, alcohol, and pack-years-adjusted odds ratios (ORs) for ATM SNP genotype calls. 
 
 
Table 7. Sex, BMI, alcohol, and pack-years-adjusted odds ratios (ORs) for ATM SNP slope-calculation. 
 
 
 
 
ATM SNP OR
95% Confidence 
Interval P-value
Intron 1 (rs4987886) 0.868 0.230-3.273 0.835
Intron 1 (rs4987889) 2.471 0.450-13.563 0.298
Intron 1 (rs228591) 0.77 0.387-1.531 0.456
Intron 16 (rs11212570) 1.191 0.500-2.833 0.693
Intron 18 (rs3092991) 4.116 1.593-10.632 0.003
Exon 30 (rs1800889) 0.634 0.157-2.563 0.523
Intron 37 (rs611646) 4.04 1.533-10.67 0.005
Intron 57 (rs17503908) 1.116 0.487-2.554 0.796
Intron 59 (rs373759) 0.954 0.544-1.673 0.869
Intron 60 (rs17174393) 1.41 0.482-4.120 0.530
ATM SNP OR
95% Confidence 
Interval P-value
Intron 1 (rs4987886) 1.773 0.959-3.275 0.068
Intron 1 (rs4987889) 0.928 0.368-2.338 0.874
Intron 1 (rs228591) 0.883 0.698-1.117 0.299
Intron 16 (rs11212570) 1.072 0.712-1.613 0.739
Intron 18 (rs3092991) 1.152 0.816-1.627 0.422
Exon 30 (rs1800889) 0.923 0.527-1.618 0.780
Intron 37 (rs611646) 1.378 1.073-1.769 0.012
Intron 57 (rs17503908) 1.235 0.820-1.860 0.312
Intron 59 (rs373759) 0.914 0.718-1.164 0.466
Intron 60 (rs17174393) 1.97 0.476-8.159 0.349
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Figure 7. Graph of rs3092991 genotype data, labeled with case/control status. 
rs3092991
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
allele A
controls
cases
 45 
5.0  DISCUSSION 
The ATM gene, located near the distal end of chromosome 11q at 11q22.3, is part of a 
region implicated in SCCHN tumor progression from dysplasia to carcinoma in situ. About 30-
76% of SCCHN tumors show loss of the distal end of chromosome 11q and subsequent 
amplification of 11q13 (32).  The protein coded by the ATM gene is a kinase that responds to 
double strand breaks by phosphorylating other key proteins involved in cell cycle control and 
DNA damage repair. ATM interacts with a large number of other proteins, such as checkpoint 
factors (CHEKs), tumor suppressors (TP53, BRCA1), DNA repair factors (RAD50, RAD51, 
GADD45) and other signaling molecules (ABL1, NFKB1).  This provides both a positional 
(chromosome 11q) and functional argument for the role of ATM in SCCHN.   
5.1.1 Study design 
ATM has long been implicated in increased risk for breast cancer through epidemiological 
studies (59).  For many years, molecular biologists were unable to uncover the ATM variations 
that conferred odds ratios such as those seen in the epidemiological studies.  Recently, however, 
a number of studies have successfully found associations that finally seem to explain the early 
epidemiological studies (56).  The success of these studies highlights the importance of an 
emphasis on study design and the careful controlling of major genetic and environmental risk 
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factors of disease.  Because BRCA1/2 play such a major role in breast cancer susceptibility, it 
was suggested that study power would be increased if ATM variation were studied in sporadic 
breast cancer cases (61).  Conversely, a study of SCCHN, which has no known major genetic 
risk factors may instead benefit by focusing on individuals from families with a history of related 
cancer (for example oral cancer or lung cancer).  If germline variations are playing a role in 
SCCHN susceptibility, we may expect to see higher rates within a family carrying one of these 
gene variants.  This type of design may therefore increase power to detecting genetic 
associations with SCCHN.   
In addition, some associations between ATM SNPs breast cancer have been found in AT 
families only, assumingly because these ATM polymorphisms are known to be deleterious (62).  
This observation seems to indicate that a study design which examines SCCHN in AT carriers 
may have greater power to detect an association; however, in a study of 1160 relatives of AT 
patients, Thompson et al. (60) only observed two cases of buccal/pharangeal cancer and three 
cases of esophageal cancer.  Therefore, although this study design may be desirable, it is likely to 
be difficult to obtain enough samples to make the data informative.  This type of design would 
also miss the effects of non-AT-causing variants in ATM. 
It may also be helpful to be able to control for HPV status in both cases and controls.  
Because HPV is a significant risk factor, with a unique etiology of disease, it would be helpful 
include HPV as a covariate when performing a regression analysis.  It would also be interesting 
to examine the role of ATM variants in relation to HPV status, as there may be variants that 
affect disease susceptibility in the presence or absence of HPV infection. 
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5.1.2 Genetic associations 
ATM has not been previously studied in SCCHN; however, a number of other cancers 
have been associated with ATM, including breast cancer and lung cancer.  Specifically, breast 
cancer studies have implicated rs228589 (61), rs36017433 (62), and IVS10-6T>G (out-of-frame 
deletion, truncation at amino acid 419) (63).  At the time of this study, these SNPs were not in 
the Hapmap database and it is unknown whether the SNPs used in this study are in LD with these 
variants. 
 Lung cancer studies (66) have found associations between a number of ATM variants and 
increased risk for disease: IVS62 +60G>A (rs664143) and the ATTA haplotype at sites: -
4518A>G (rs189037), IVS21 -77C>T (rs664677), IVS61 -55T>C (rs664982) and IVS62 
+60G>A (rs664143).  The previously associated SNPs in the haplotype (above) are in high LD 
with each other (84-98%).   In addition, the variant, IVS48+238 C>G (rs609429) has been 
associated with decreased risk for lung cancer (67).  This SNP is also not in the Hapmap 
database and it is unknown whether any of the SNPs included in this study are in LD with 
rs609429. 
This study analyzed both genotype calls and the slope-calculation for each SNP and 
found significant associations with three ATM SNPs and risk for SCCHN: rs611646, rs373759, 
and rs3092991.   
Rs611646: Located in intron 37, this SNP was included in the study as a tag-SNP.  This SNP is 
part of a large haplotype block, containing many SNPs with an R2 value of 1.0.  This makes it 
difficult to locate a functional SNP responsible for this observation. 
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Rs373759: This SNP was also picked as a tag-SNP and is located in intron 59.  Together with 
rs611646, rs373759 is in the same large haplotype block as rs664143 and confirms previous 
findings that associated this SNP with lung cancer (66). 
Rs3092991 was only found to be associated with disease in the slope-calculation analysis.  This 
analysis was performed on every SNP due to data quality concerns and effectively assigned a 
single slope-value to each data point.  This finding was particularly puzzling in that the data for 
this SNP was one of the highest quality and genotype calls were thought to be very reliable.  It 
was hypothesized that differences between the slope-calculation and genotype analysis would be 
possible if there were subgroups of cases or controls that clustered within the larger genotype 
groups.  Upon visual inspection of the data distribution, there did not appear to be any such sub-
clustering.  In addition, when genotypes were examined separately, no associations were found 
in the genotype data.  This association may be an artifact of the distribution of data in that the 
major allele shows higher background for this SNP as raw intensities rise.  This causes a slight 
curving of the distribution and may make the slope-calculation less accurate than genotype calls, 
themselves. 
 
5.1.3 Epidemiology 
Basic epidemiological analyses replicated findings of previous studies, showing that 
alcohol [OR=2.0, (CI:1.2-3.3)], cigarette smoking, in terms of “pack-years” [OR=2.3, (CI:1.7-
3.2); OR=1.5], and male gender [OR=1.7, (CI:1.2-2.3)] appear to be major risk factors for 
disease.  Age was not found to be associated with disease, however, these analyses are not 
meaningful given that cases and controls were age-matched as part of the study design.  A 
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comprehensive analysis of interactions between these variables was not performed, as this was 
not the focus of the study.  However, examination of SNP associations and ORs before 
regression and after regression did not reveal any significant interaction between the SNPs and 
epidemiological risk factors.  Further analyses that stratify according to risk factors, 
simultaneously (eg. smoking and alcohol status), may provide further insight into the mechanism 
of SNP associations.  Lower BMIs (18.6-25.0 kg/m2) were also associated with disease [OR=1.7, 
(CI:1.24-2.38)], although this may be a result of disease, rather than a cause. 
 
5.1.4 Future directions 
The significant associations found in the study warrant further haplotype analyses in the 
region of rs611646 and rs373759.  Preliminary results of the multi-locus genotype analysis can 
be seen in Table 8.  Future analyses should also examine interactions between genotypes and 
covariates, especially in the presence/absence of smoking and alcohol.  This may give further 
insight into the role of ATM in disease and possible biological mechanisms of association.  
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Table 8. Joint genotype analysis of rs611646 and rs373759. 
 
 
Finally, sample quality was a major issue in this study.  Because very little genomic DNA 
was available, it was necessary to perform a -genome amplification.  This greatly reduced the 
data quality and made a number of assays difficult to interpret.  In an attempt to correct for the 
difficulty in making accurate genotype calls, a new unbiased calculation was performed (the 
slope-calculation).  This calculation effectively gave a value to the slope of each data-point from 
the origin and could be used similar to other variables in the regression analyses.  For nine out of 
ten SNPs analysis of this slope-calculation agreed with the conclusions of the genotype calls.  In 
one SNP, however (rs3092291), the analysis of the slope-calculation showed significance 
whereas the genotype call data did not.  An attempt was made to explain this observation, and it 
is this author’s opinion that the unusual distribution of the data may have caused the discrepancy. 
Further examination of genotype data for SNP rs3092991 is necessary to tease apart differences 
in the two methods of data-calling, and interpret results of this SNP. 
 
 
 
rs611646/rs373759 Cases % Controls %
AA/CC 3 1.3 4 1.5
AA/CT 8 3.5 22 8.4
AA/TT 30 13.0 28 10.7
AT/CC 26 11.3 29 11.1
AT/CT 59 25.7 87 33.3
AT/TT 1 0.4 2 0.8
TT/CC 101 43.9 84 32.2
TT/CT 1 0.4 5 1.9
TT/TT 1 0.4 0 0.0
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